T
The Community Research of South Florida | Hialeah, FL
Research site
(Unclaimed)
Site insights
Top conditions
Top treatments
Dapagliflozin
BMS-512148
Lebrikizumab
CS02
Diclofenac Sodium Gel
Naproxen
Upadacitinib
Metformin
BLU-5937
MHAA4549A
Data sourced from clinicaltrials.gov
Work at this site?
CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.
Active trials
2 of 16 total trials
This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).
Enrolling
Refractory Chronic Cough
Drug: BLU-5937
Drug: Placebo
This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.
Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab
Trial sponsors
B
C
I
Clinical trials
Research sites
Resources
Legal
© Copyright 2024 Veeva Systems